# Latigo Biotherapeutics, Inc. — capital_raise/public_offering [announced]
Source: SEC API (secapi.ai) · situation sit_35573a454c09f9c1b3f3 · retrieved 2026-08-11T16:13:20.272Z

## Overview
Latigo Biotherapeutics is a clinical-stage biopharmaceutical company committed to developing innovative non-opioid pain medicines designed to rapidly and effectively stop the transmission of pain without the risk of addiction, with lead candidates LTG-001 and LTG-321 being oral Na v 1.8 inhibitors.

Latigo Biotherapeutics, Inc., a clinical-stage biopharmaceutical company developing non-opioid pain medicines, is conducting an initial public offering of 19,200,000 shares of common stock at $18.00 per share, generating gross proceeds of $345,600,000. The company's common stock has been approved for listing on The Nasdaq Global Select Market under the symbol "LTGO". Underwriters have been granted a 30-day option to purchase up to an additional 2,880,000 shares. The underwriters expect to deliver the shares on August 10, 2026.

## Terms
- Counterparty: Goldman Sachs & Co. LLC, Jefferies, Leerink Partners, Guggenheim Securities (underwriters) · Deal value: $345.6M · Consideration: cash · Price/share: $18

## Key dates
- Announced 2026-08-03 · Expected close 2026-08-10

## Timeline
- 2026-08-03 · S-1/A (0001193125-26-329431): S-1/A - Latigo Biotherapeutics, Inc. — *Latigo Biotherapeutics is a clinical-stage biopharmaceutical company developing innovative non-opioid pain medicines designed to inhibit Na v 1.8 ion channels; its lead candidate LTG-001 is an oral Na v 1.8 inhibitor in Phase 3 development for acute pain, and LTG-321 is a next-generation candidate for chronic musculoskeletal pain.* Latigo Biotherapeutics, Inc., a clinical-stage biopharmaceutical company developing non-opioid pain medicines, is conducting an initial public offering of 16,000,000 shares of common stock at an expected price range of $16.00 to $18.00 per share. The company has no prior public market for its common stock. Based on an assumed midpoint price of $17.00 per share, the company estimates net proceeds of approximately $247.2 million (or $285.2 million if underwriters exercise their option to purchase 2,400,000 additional shares), after deducting underwriting discounts and estimated offering expenses. The company intends to use proceeds to advance development of its lead candidate LTG-001 through Phase 3 trials and NDA submission, advance LTG-321 through Phase 2 proof-of-concept and into Phase 3, and fund other research and development activities.
  https://www.sec.gov/Archives/edgar/data/2056611/0001193125-26-329431.txt
- 2026-08-04 · S-1/A (0001193125-26-331205): S-1/A - Latigo Biotherapeutics, Inc. — *Latigo Biotherapeutics is a clinical-stage biopharmaceutical company developing innovative non-opioid pain medicines designed to inhibit Na v 1.8, a voltage-gated sodium channel involved in pain transmission, with lead candidates LTG-001 (oral Na v 1.8 inhibitor for acute pain) and LTG-321 (next-generation Na v 1.8 inhibitor for chronic musculoskeletal pain).* Latigo Biotherapeutics, a clinical-stage biopharmaceutical company developing non-opioid pain medicines, is conducting an initial public offering of 16,000,000 shares of common stock at an expected price range of $16.00 to $18.00 per share. The company's lead candidate, LTG-001, is an oral Na v 1.8 inhibitor in Phase 3 development for acute pain, with positive Phase 2 data from an abdominoplasty trial showing ~50% greater analgesic effect than Vicodin and 52.3% of patients remaining opioid-free. The company also has LTG-321 in Phase 2 development for chronic musculoskeletal pain and LTG-418 in preclinical development. Net proceeds are estimated at approximately $247.2 million (assuming a $17.00 midpoint price), to be used for advancing LTG-001 through Phase 3 and NDA submission, advancing LTG-321 through Phase 2 proof-of-concept and into Phase 3, and other R&D activities.
  https://www.sec.gov/Archives/edgar/data/2056611/0001193125-26-331205.txt
- 2026-08-07 · 424B4 (0001193125-26-340329): 424B4 - Latigo Biotherapeutics, Inc. — *Latigo Biotherapeutics is a clinical-stage biopharmaceutical company committed to developing innovative non-opioid pain medicines designed to rapidly and effectively stop the transmission of pain without the risk of addiction, with lead candidates LTG-001 and LTG-321 being oral Na v 1.8 inhibitors.* Latigo Biotherapeutics, Inc., a clinical-stage biopharmaceutical company developing non-opioid pain medicines, is conducting an initial public offering of 19,200,000 shares of common stock at $18.00 per share, generating gross proceeds of $345,600,000. The company's common stock has been approved for listing on The Nasdaq Global Select Market under the symbol "LTGO". Underwriters have been granted a 30-day option to purchase up to an additional 2,880,000 shares. The underwriters expect to deliver the shares on August 10, 2026.
  https://www.sec.gov/Archives/edgar/data/2056611/0001193125-26-340329.txt

## Citations
- 0001193125-26-329431 — https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&type=&dateb=&owner=include&count=40&search_text=000119312526329431
- 0001193125-26-331205 — https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&type=&dateb=&owner=include&count=40&search_text=000119312526331205
- 0001193125-26-340329 — https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&type=&dateb=&owner=include&count=40&search_text=000119312526340329